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TransportThe mechanisms underlying trafﬁcking and membrane targeting of EAAC1, the rodent counterpart of the
human EAAT3 carrier for anionic amino acids, are well characterized. In contrast, much less is known on the
regulation of Slc1a1, the gene that encodes for the transporter. We have recently found that all-trans retinoic
acid (ATRA) stimulates EAAC1 expression and anionic amino acid transport in C6 rat glioma cells. We report
here that the ATRA effect on EAAC1 activity was inhibited by the speciﬁc RAR antagonist LE540 and
mimicked by Am80, a RAR agonist, but not by the RXR agonist HX630. Moreover, the ATRA-dependent
induction of Slc1a1 mRNA required the synthesis of a protein intermediate and was not associated with
changes in the messenger half-life. ATRA treatment induced the expression of both Rarb mRNA and RARβ
protein several hours before the induction of Slc1a1, while the mRNA for RFX1, a transcription factor recently
involved in Slc1a1 transcription, was unchanged. In addition, Rarb silencing markedly inhibited the ATRA-
dependent increase of both Rarb and Slc1a1 mRNAs. We conclude that in C6 glioma cells the induction of
Slc1a1 by ATRA requires the synthesis of RARβ, suggesting that the receptor is involved in the regulation of
the transporter gene.© 2009 Elsevier B.V. All rights reserved.1. Introduction
The glutamate transporter EAAT3 and its rodent counterpart
EAAC1, although present in several cell types, are mainly expressed
in central nervous system (CNS) neurons [1]. As other members of the
EAAT family, EAAC1, which is encoded by the Slc1a1 gene, is involved
in the regulation of the extracellular glutamate concentration and in
synaptic plasticity [2]. Alterations in the activity and/or expression of
the transporter have been implied in several neurological and
psychiatric conditions [3]. For these reasons, the regulation of
EAAC1/EAAT3 activity has been investigated in a number of studies
(see [3] for a recent review). Most of these involve rapid mechanisms
that modify transporter trafﬁcking between the plasma membrane
and intracellular compartments, where most of the carrier proteins
are located [4].ntral Nervous System; DMEM,
Amino Acid Carrier 1; EAAT,
nced Salt Solution; FBS, Fetal
RAR, Retinoic Acid Receptors;
ale e Clinica, Dipartimento di
urno, 39, 43100 Parma, Italy.
ti).
ll rights reserved.Much less is known about EAAC1/EAAT3 regulation at the gene
level. Ma et al. [5] have shown that the transfection of rat glioma C6
cells with the human transcription factor RFX1 induces EAAC1
expression. More recently, we have found that in the same cell
model the chronic exposure to all-trans retinoic acid (ATRA) causes a
marked induction of Slc1a1, causing the increased abundance of
EAAC1 carrier proteins and the proportional stimulation of transport
activity [6]. Under the same conditions, no induction of Slc1a2 (for the
GLT-1 transporter) or Slc1a3 (for the GLAST transporter) is observed
[6], suggesting that inducibility by ATRA is a peculiarity of Slc1a1, at
least in C6 cells. In this cell model ATRA treatment also causes the
increased expression of Plp, a marker of the oligodendrocytic
differentiation pathway and a well known ATRA target gene [7]. The
induction of Plp mRNA by ATRA in C6 cells is a slow phenomenon,
requires a protein intermediate and has been attributed to an increase
in the half-life of the messenger [8].
A variety of genes are direct or indirect targets of retinoids and
their expression is modulated by ATRA at both transcriptional and
post-transcriptional levels. In particular, the transcription of direct
ATRA targets is promoted by a complex formed by ATRA, a
heterodimer of RAR–RXR receptors and several other co-stimulator
molecules. Indirect regulation of gene expression by ATRA comprises
various mechanisms such as (a) the induction of an intermediary
(usually a transcription factor) that is directly responsible for the
effect, (b) the modulation of mRNA stability, and (c) the interaction
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Moreover, retinoids can affect transcription through non genomic
effects, such as the modulation of MAPK cascade [10] or of Akt
signaling pathway [11].
The essential step required for the direct transcriptional effects of
ATRA is represented by the interaction of the retinoid with the
heterodimer formed by a member of RAR receptor family and a RXR
receptor. For each of the three RAR subtypes (α, β, and γ), several
isoforms exist that differ for their N-terminal regions [12]. There are
two major isoforms for RARα (α1 and α2) and for RARγ (γ1 and γ2)
and four major isoforms for RARβ (β1 and β3, initiated at the P1
promoter, and β2 and β4, initiated at the P2 promoter). Two isoforms
also exist for each of the three RXR receptors thus far characterized (α,
β, and γ) [13]. Upon the interaction with the ligand, the RAR–RXR
heterodimer exchanges co-repressor partners with co-activators and
the transcription of the target gene can start. While RARα is expressed
inmost tissues [12], the expression of RARβ and RARγ is tissue speciﬁc
and highly regulated [14]. Interestingly, two of the RARβ isoforms,
RARβ2 and 4, are transcribed from a promoter that contains a DR5
sequence and, hence, are inducible by retinoids [15,16]. Consistently,
ATRA treatment markedly affects the expression of RARβ receptors in
many cell types. In particular, in C6 cells ATRA stimulates the
expression of one of the “heavy”, 55 kDa isoform of RARβ, while
RARα is not affected by the retinoid [17].
In this report we have studied the mechanisms underlying the
effect of the retinoid on EAAC1, obtaining evidence that involves the
synthesis and the activation of a RARβ receptor as one of the steps in
the regulatory process.
2. Methods and materials
2.1. Cells and treatments
The rat CNS-derived C6 glioma cells were obtained from the
AmericanType Culture Collection (Rockville, MD). Cells were grown at
37 °C and 5% CO2 in Dulbecco's modiﬁed Eagle Medium (DMEM),
supplemented with 10% fetal bovine serum (FBS), 4 mM glutamine,
100 units/ml penicillin, and 100 μg/ml streptomycin. Cells were used
for less than 10 passages from thawing with no apparent change in
morphology or sensitivity to treatments.
For ATRA treatment, unless otherwise speciﬁed, culture medium
was substituted 12 h after the passage with fresh medium supple-
mentedwith 0.1% FBS in the absence or in the presence of ATRA. ATRA,
obtained from Sigma, was used at the concentrations detailed for each
experiment starting from a 10 mM stock solution in DMSO. The RAR
and RXR agonists were synthesized by one of us (HK) according to the
methods reported previously [18–20]. The identiﬁcation and purity of
the compounds were determined by melting point, NMR, and Mass
Spectroscopy. The compounds are very stable to heat, light, acids and
bases and do not decompose under the experimental conditions
adopted. RAR and RXR agonists and inhibitors were used at the
concentrations detailed in the experiments starting from stock
solutions in DMSO (10 mM, 10 mM, 1 mM, and 1 mM for, respectively,
Am80, HX630, LE540 and HX531). In the controls, the vehicle was
used at the maximal concentration adopted in the single experiment.
2.2. Transport activity
The initial inﬂux of D-[3H]aspartate, a high-afﬁnity substrate of
EAATs [1], was measured in 96-well multidish plates (Falcon, Becton,
Dickinson Biosciences, Franklin Lakes, NJ, USA), where C6 cells had
been seeded at a density of 10 ·103 cells/well, or in Falcon 24-well
multidish plates, where cells had been seeded at a density of
50· 103 cells/well. For the experiments, cells were washed twice in
a modiﬁed EBSS (Earle's Balanced Salt Solution, containing (in mM)
117 NaCl, 5 KCl, 1.8 CaCl2, 1 NaH2PO4, 0.8 MgSO4, 5.5 glucose, bufferedwith 20 mMHEPES-NaOH at pH 7.4) and incubated in the same saline
solution supplemented with D-[3H]aspartate (1 μM, 2 μCi/ml) for
1 min.
At the end of the assay, multiwell dishes were washed twice with
ice-cold urea (300 mM) and cell monolayers were extracted with
absolute ethanol. The extracts were added to scintillation ﬂuid and
counted with a Wallac Trilux2 liquid scintillation spectrometer
(Perkin-Elmer, Boston, MA, USA). Cell proteins were determined
directly in the well with a modiﬁed Lowry procedure and measured
with a Wallac Victor2 Multilabel Counter (Perkin-Elmer). Amino acid
inﬂux is expressed as pmoles mg of protein−1·min−1.
2.3. RT-qPolymerase Chain Reaction
Total RNAwas isolated with RNeasyMini Kit® (Qiagen S.p.a., Milan,
Italy). After reverse transcription, 25 ng of cDNA from each sample
was ampliﬁed in a total volume of 25 μl with 2× SYBRGreen qPCR
SuperMix-ROX (Rovalab, Taltow, Germany), along with the following
forward and reverse primers (5 pmol each) for the genes: 5′ CGA CTT
GCC GTA CCT GGA CT 3′ and 5′ GCC CAC GGG ACT CAA CAC GA 3′ for
Slc1a1; 5′ ATA CCC CAG AGC AAG ACA CC 3′ and 5′ AGC AGA TGG CAC
TGA GAA GA 3′ for Rarb; 5′ ACT GCC TCT TTC TTC TTC CT 3′ and 5′ ATT
TTC CCA AAC AAT GAC AC 3′ for Plp; 5′ AAC CAGAGAGCC GAT TTTAGA
G 3′ and 5′ AAC TGT TGC TAC CCA CCC TAC T 3′ for Rfx1; 5′ AGC CTC
AAG ATC ATC AGC AAT G 3′ and 5′ CAC GAT ACC AAA GTT GTC ATGGA
3′ for Gapdh. All the primers were designed with the help of Primer 3
program [21] according to the known or predicted (in the case of
Rfx1) rat sequences reported in GenBank. Quantitative PCR was
performed in a 36 well Rotor-Gene 3000 (Corbett Research, Rotor-
Gene™ 3000, version 5.0.60, Mortlake, Australia). For all the probands
each cycle consisted of a denaturation step at 95 °C for 30 s, followed
by separate annealing (30 s) and extension (30 s) steps at a
temperature characteristic for each proband. Fluorescence was
monitored at the end of each extension step. A no template, no-
reverse transcriptase control was included in each experiment. At the
end of the ampliﬁcation cycles a melting curve analysis was added.
The analysis of the data was made according to the Relative Standard
CurveMethod [22]. qRT-PCR datawere expressed as the ratio between
proband mRNA and Gapdh mRNA.
2.4. Western analysis
For RARβ expression, protein extraction and quantiﬁcation were
performed with the method of Farinha et al. [23] with minor
modiﬁcations. C6 cells, grown to subconﬂuence on 10-cm tissue
culture plates, were rinsed twice in PBS and lysed in 300 μl of Sample
Buffer 1× (31.25 mM Tris–HCl pH 6.8, 3% SDS, 10% glycerol, 100 mM
DTT, 0.02% bromophenol blue). After solubilization, cell lysates were
collected in Eppendorf tubes and passed 10 times into 25 G and then
27 G needles. The quantiﬁcation of proteins was performed with a
modiﬁed Lowry assay [23]. Brieﬂy, the protein sample was added with
1 ml of H2O and 100 μl of sodium deoxycholate (0.15%) and the
mixture incubated for 10 min. At the end of this period, 100 μl of 72%
trichloroacetic acid was added to the sample that was vortexed and
span at 14,000 rpm for 5 min at room temperature. The supernatant
was removed and the pellet was resuspended in 400 μl of H2O,
supplemented with 400 μl of reagent A (1 volume of CTC; 1 volume of
10% sodium dodecyl sulphate; 1 volume of 0.8 M NaOH; 1 volume of
H2O, where CTC is a mixture of 25 ml of 0.4% CuSO4∙5H2O, 25 ml of
0.8% potassium tartrate, and 200 ml of 5% Na2CO3), incubated for
10 min, and added with 200 μl of Reagent B (1 volume of Folin–
Ciocalteau reagent +4 volumes of H2O). Absorbance at 750 nm was
read after 30 min and protein content was calculated from bovine
serum albumin standards. Aliquots of 60 μg were loaded on a 10% gel
for SDS-PAGE. After the electrophoresis, proteins were transferred to
nitrocellulose membranes (Schleicher and Schuell Bioscience, Dassel,
Fig. 1. Effect of RAR and RXR agonists and antagonists on ATRA-dependent increase of
EAAC1 activity. C6 cells were seeded in 96-well (Panel A) or in 24-well multiwell dishes
(Panels B and C). After 24 h, cells were incubated in the absence (control, empty bars) or
in the presence of the indicated agonists or antagonists (solid bars), as detailed in each
panel. Transport of D-Asp was measured after 3 days. Bars are means±SD of ﬁve (Panel
A) or three (Panels B and C) independent determinations in representative experi-
ments, repeated twice with comparable results. For all panels, ⁎⁎Pb0.01, ⁎⁎⁎Pb0.001 vs.
control cells; ns, not signiﬁcant vs. control cells; for panel A, ###Pb0.001 vs. cells treated
with ATRA and vs. cells treated with 1 μM Am80; for panel B, ###Pb0.001 vs. cells
treated with ATRA and vs. cells treated with 50 nM ATRA, $$$Pb0.001 vs. cells treated
with 20 nM ATRA; for panel C, ###Pb0.001 vs. cells treated with 1 μM HX531, §Pb0.05
vs. cells treated with 50 nM ATRA.
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tion in PBS-Tween 0.1%, containing 5% of non fat dried milk
(Amersham Pharmacia Biotech Italia, Milan, Italy), for 2 h at room
temperature. The blots were then exposed overnight at 4 °C to anti-
RARβ1-2 (1:250) or anti RARα polyclonal antisera (1:200), obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA), diluted in
blocking solution. After washing, the blots were exposed for 1 h to
horseradish peroxidase-conjugated anti-rabbit IgG (ExactaCruz, Santa
Cruz Biotechnology) diluted 1:10000 in blocking solution. For the
standardization of the total cell lysate and the intracellular fraction,
stripped membranes were exposed to monoclonal antiserum against
GAPDH (Chemicon International Inc., Temecula, CA, USA, 1:1000). The
membranes were washed and the immunoreactivity visualized with
enhanced chemiluminescence (Millipore, Billerica, MA).
The Western Blot analysis of EAAC1 expression was performed as
described by Bianchi et al. [6].
2.5. Silencing experiments
Silencing of Rarb mRNA was carried out in C6 cells using the N-
TER™ Nanoparticle siRNA Transfection System from Sigma-Aldrich.
The same manufacturer provided also the oligonucleotides against rat
Rarb1-2 (oligos #3834795 and #3834796 (siRNA1); oligos #3834797
and #3834798 (siRNA2); oligos #3834799 and #3834800 (siRNA3))
and the scrambled siRNAs (oligos #3834801 and #383802). The
preparation of oligonucleotide/peptide mixtures was performed
according to the manufacturer's instructions.
The protocols used for Rarb silencing are detailed in the legends of
the single experiments.
2.6. Statistical analysis
Statistical analysis of transport data was performed with a one-
way ANOVA with the Bonferroni post hoc test. qRT-PCR data were
analyzed with a t-test for unpaired data (Fig. 5) or with a one-way
ANOVA with the Bonferroni test for selected pairs of conditions (Figs.
3 and 8). In all cases, P valuesN0.05 were considered not signiﬁcant.
2.7. Materials
FBS and culture medium were purchased from Celbio, (Pero, MI,
Italy). D-[2,3-3H]aspartic acid (12 Ci/mmol) was obtained from
Perkin-Elmer (Monza, Italy). Sigma was the source of the other
chemicals, including ATRA, whenever not stated otherwise.
3. Results
3.1. ATRA-dependent EAAC1 stimulation is mimicked by RAR agonists
and inhibited by RAR but not by RXR inhibitors
To investigate the mechanism underlying Slc1a1 induction in
ATRA-treated cells we examined the effects of agonists or antagonists
of RAR and RXR receptors on the ATRA-dependent stimulation of
EAAC1 transport activity. The results of this analysis, recounted in
Fig. 1, indicate that the speciﬁc Retinoic Acid Receptor (RAR) agonist
Am80 mimicked the maximal ATRA effect, while the RXR agonist
HX630 was ineffective (Panel A). However, cells treated simulta-
neously with Am80 and HX630 exhibited a transport activity for
aspartate signiﬁcantly higher than cells treatedwith 1 μMATRA. These
data closely reﬂect the behaviour of EAAC1 protein, as shown in Fig. 2.
Indeed, besides ATRA, also Am80 caused an evident EAAC1 over-
expressionwhile treatment with HX630 did not substantially increase
transporter expression. The highest level of EAAC1 expression was
detected upon the simultaneous exposure to Am80 and HX630.
Fig. 1, Panels B and C, reports the results obtained with RAR and
RXR antagonists. These experiments, in which ATRA was used at low,
Fig. 2. Effects of RAR or RXR agonists on EAAC1 expression in C6 cells. C6 cells were
incubated for 72 h in the absence or in the presence of ATRA (1 μM), the RAR agonist
Am80 (1 μM), the RXR agonist HX630 (1 μM), or both agonists. Cells were then lysed
and lysates examined for the expression of EAAC1. GAPDHwas used as a loading control.
The lower part of the ﬁgure reports the densitometric analysis of the blot. The
experiment was repeated twice with comparable results.
Fig. 3. Dependence of Slc1a1 induction upon protein synthesis. C6 cells were incubated
for 3 days in the absence or in the presence of 1 μMATRA and of 5 μg/ml cycloheximide.
At the end of this period, the relative abundance of Slc1a1, Plp, and Rarb mRNA was
determined with RT-PCR. Data are means±SD of four determinations obtained in two
different experiments. ⁎Pb0.05, ⁎⁎Pb0.01, ⁎⁎⁎Pb0.001 vs. respective control, ATRA-
untreated cells; ns, not signiﬁcant vs. respective, ATRA-untreated controls.
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nist LE540 signiﬁcantly inhibited the effect of 50 nM ATRA and
completely suppressed transport stimulation at 20 nM ATRA (Panel
B). On the contrary, ATRA effect was not inhibited by 1 μM HX531, an
RXR antagonist that also inhibits RARs at high concentrations, but was
signiﬁcantly loweredwhen the inhibitor was used at 2.5 μM (Panel C).
In summary, these results indicate that the ATRA-dependent stimula-
tion of EAAC1 transport activity requires the interaction of the retinoid
with a RAR receptor.
3.2. Slc1a1 induction requires protein synthesis and does not involve
changes in the messenger half-life
ATRA-dependent stimulation of EAAC1 activity is associated with
the increase in the level of Slc1a1 mRNA [6]. To investigate the
mechanism underlying this effect we have performed ATRA treatment
in the presence of the protein synthesis inhibitor cycloheximide and
compared the behaviour of the transporter messenger with that of
other two ATRA target mRNAs, Rarb, encoding for the RARβ receptor,
and Plp, which encodes for the proteolipid protein (Fig. 3). The results
obtained indicate that the inhibitor completely suppressed the
increase in Slc1a1 mRNA levels caused by ATRA, demonstrating that
the ATRA-dependent stimulation of Slc1a1 expression requires the
new synthesis of a protein. The requirement for active protein
synthesis is not shared by all the other ATRA target genes. Indeed,
the mRNA for RARβ was still signiﬁcantly increased by ATRA even in
the presence of cycloheximide while the ATRA-dependent inductionof Plp mRNA was not detectable under the same conditions (see also
[8]). However, both Rarb and Plp mRNAs were signiﬁcantly more
abundant in cells treated with cycloheximide, even in the absence of
ATRA (Panels B and C). Moreover, the effects of ATRA and
cycloheximide on Rarb expression were clearly additive (panel B).
These results, consistent with previous observations [24,25], indicated
that in C6 cells Rarb is superinduced by the protein synthesis inhibitor.
Although the mechanisms underlying gene superinduction by
cycloheximide are not fully understood, they are usually attributed
to decreased mRNA degradation or increased stabilization of nuclear
receptors [26–28].
ATRA-dependent increase of Plp mRNA is particularly interesting
since it is an example of ATRA effect at post-transcriptional level,
being mediated through changes in the half-life of the messenger
[8]. The possibility that the same mechanism operates in ATRA-
dependent stimulation of Slc1a1 expression has been investigated
Fig. 4. ATRA effects on the half-life of Slc1a1, Rarb and Plp mRNAs. C6 cells were
incubated for 24 h in the absence or in the presence of 1 μM ATRA. After this period,
2.4 μM actinomycin D was added to the extracellular medium and incubation
prolonged, with or without ATRA, for further 12 h. At the indicated times, RNA was
extracted and the expression of the indicated genes (Panel A, Slc1a1; Panel B, Rarb;
Panel C, Plp) was determined through RT-PCR. Points are means of four determinations
obtained in two distinct experiments. Lines represent the best ﬁt linear regressions. The
slopes of the regression lines obtained in the absence and in the presence of ATRAwere
signiﬁcantly different (Pb0.01) only for Plp (Panel C).
Fig. 5. ATRA effects on gene expression in C6 cells. C6 cells were incubated for the
indicated times in the absence or in the presence of 1 μM ATRA. At the indicated times,
RNA was extracted and the expression of the indicated genes (Panel A, Slc1a1; Panel B,
Rfx1; Panel C, Rarb) was determined through RT-PCR. Data are expressed relatively to
GapdhmRNA abundance and aremeans of four determinations obtained in two distinct
experiments. ns, not signiﬁcant, ⁎Pb0.05, ⁎⁎Pb0.01 vs. control, ATRA-untreated cells
extracted at the same experimental time.
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to block transcription, and determining mRNA levels at different
times of incubation. The results (Fig. 4A) indicate that during the
incubation with actinomycin D the time course of the ratio between
Slc1a1 and Gapdh mRNAs was not statistically different in control
and ATRA-treated cells. The behaviour of Rarb mRNA (Fig. 4B) is
comparable, while, as expected [8], the ratio of Plp and Gapdh
mRNAs increased progressively if the incubation in the presence of
actinomycin was performed in ATRA-treated cells, indicating that
the half-life of Plp messenger is longer in the presence of the
retinoid than in its absence.3.3. Slc1a1 induction is preceded by Rarb but not by Rfx1 induction
The transfection of C6 cells with the human transcription factor
RFX1 has recently been reported to activate Slc1a1 expression [5].
Interestingly, RFX1 protein is induced by ATRA in human myeloid
models [29]. Thus, although no direct evidence is available about ATRA
sensitivity of the rat Rfx1 gene, the possibility exists that the protein
intermediate required for Slc1a1 induction is RFX1. In order to verify
this hypothesis, we have performed a short-term time course of
Slc1a1 and Rfx1 mRNAs during ATRA treatment (Fig. 5). The results
indicate that, while a signiﬁcant Slc1a1 induction is detected at 16 h of
treatment as well as at longer times (Panel A), Rfx1 is not induced at
any time during ATRA treatment (Panel B). Rather, a moderate
decrease in the expression levels of the transcription factor is detected
Fig. 6. Induction of RARβ by ATRA in C6 cells, C6 cells were incubated for the indicated
times in the absence or in the presence of 1 μM ATRA. Cells were then lysed and the
lysates were examined for the expression of RARβ. GAPDH expression was used as a
loading control. The lower part of the ﬁgure reports the densitometric analysis of the
results. The experiment was repeated twice with comparable results.
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presence of the retinoid. Consistently, no increase in RFX1 protein is
detected during ATRA treatment up to 72 h of treatment (data not
shown).
As expected from literature [8], a rapid, ATRA-dependent induction
of Rarb is instead detectable from the earliest time of treatment (4 h)
and still observed, although at lower levels, after 48 h (Panel C). The
fast induction of RARβ under our experimental conditions has been
conﬁrmed at protein level, through a Western Blot that, moreover,
indicated that the induction of the receptor was an early change
induced by ATRA. The primary antibody used in this experiment
recognizes several RARβ isoforms and, consistently, at least two bands
are induced during the treatment while a third band, already present
under control conditions, is enhanced (Fig. 6). The densitometric
analysis indicates that the maximal expression of the receptor is
detected at 4 h to decrease at later times, although it is still clearly
detectable at 24 h.
Under the same conditions no changes in RARα expression were
detected either at mRNA or protein level (not shown).Fig. 7. Effects of anti-Rarb-siRNA on the ATRA-induced expression of Rarb. The culture
medium of C6 cells was replaced with medium containing 10% FBS and the anti-Rarb
siRNA/peptide or scrambled siRNA/peptide complexes (as indicated, see Methods).
After 24 h, mediumwas renewed againwith a fresh, siRNA-freemedium, supplemented
with 0.1% FBS, in the absence or in the presence of ATRA 1 μM.mRNAwas extracted after
8 h and the abundance of Rarb and Gapdh mRNAs was determined with RT-PCR. Data of
Rarb mRNA abundance are expressed relatively to Gapdh mRNA and are means of two
determinations with SD in a representative experiment. The experiment was repeated
twice with comparable results.3.4. Slc1a1 induction is inhibited by Rarb silencing
To directly evaluate the role of RARβ in ATRA effects on Slc1a1,
we used a silencing approach aimed to interfere with Rarb
induction by ATRA. We preliminarily tested three siRNAs (1, 2, 3),
targeted to Rarb1-2 mRNAs, at two different concentrations and
found that scrambled siRNA did not affect the induction of Rarb
caused by a 8h-incubation with ATRA. Rarb induction was instead
markedly affected by one of the three anti-Rarb siRNAs used
(siRNA-2). Rarb silencing by siRNA-2 was dose-dependent, with a
70% inhibition of ATRA-dependent induction observed with a
concentration of 50 nM (Fig. 7). The inhibitions observed with the
other two siRNAs were smaller and poorly dose-dependent.
Attempts to use combinations of low concentrations of two siRNAs
or prolongation of ATRA treatment over 24 h yielded smaller
inhibitions than those observed with siRNA-2 alone after a 24h-
ATRA treatment (not shown).
We then tested the effects of siRNA-2 on Slc1a1 induction by ATRA.
In these experiments we had to perform ATRA treatment for 24 h so as
to achieve a signiﬁcant Slc1a1 induction. To maintain an effective
silencing for this relatively long time, we decided to prolong the
exposure to siRNA throughout ATRA treatment, raising the FBS
concentration to 10% and ATRA concentration to 10 μM (see the
legend to Fig. 8 for experimental details). Under these conditions,
Rarb-silenced cells exhibited an effective inhibition of both Rarb and
Slc1a1 ATRA-dependent induction (Fig. 8A and B). In cells treated
with the scrambled siRNA, ATRA increased Slc1a1 expression by 140%Fig. 8. Effect of RARβ silencing on the ATRA-induced expression of Slc1a1. The culture
medium of C6 cells was replaced with serum free medium containing the anti-Rarb
siRNA/peptide or scrambled siRNA, both at a concentration of 100 nM, and the
incubation was prolonged for 4 h. An equal volume of medium supplemented with 20%
FBS was then added to each culture so as to lower the siRNA concentration at 50 nM and
to raise the FBS concentration to 10%. After 20 h, ATRA (10 μM) or vehicle was added to
the incubation medium. mRNA was extracted after further 24 h of incubation and the
abundance of Rarb (Panel A) and Slc1a1 (Panel B) was determined with RT-PCR. Data
represent means of three determinations in a representative experiment repeated twice
with comparable results.
1867M.G. Bianchi et al. / Biochimica et Biophysica Acta 1788 (2009) 1861–1868(Fig. 8B), while the modest induction observed in Rarb-silenced cells
(35%) was not signiﬁcant.
4. Discussion
ATRA is a major regulator of gene expression in eukaryotes and the
expression of several hundreds of genes is affected by this retinoid.
However, only a portion of these genes are directly activated by the
ATRA according to the classical mechanism of binding and activation
of a heterodimeric complex of RAR–RXR receptors. In many other
cases, ATRA works indirectly through several mechanisms, the best
known of which involve the synthesis of factors that, conversely,
target gene transcription or cause changes in messenger half-life. The
results recounted in this contribution imply RARβ as the mediator of
ATRA effects on EAAC1 transporter. This conclusion is based on several
lines of evidence.
First, the pharmacological characterization of ATRA-dependent
stimulation of EAAC1 activity (Fig. 1) or expression (Fig. 2) strongly
suggests that one or more receptors of the RAR family are involved
since the RAR-speciﬁc agonist Am80 fully mimicked ATRA effect.
Interestingly, under the same conditions, the synthetic rexinoid
HX630 does not increase aspartate transport and EAAC1 expression,
but, in its presence, Am80 produces a greater stimulation than in
its absence. This synergistic effect may be explained given that
RXRs are unable to respond to rexinoids (RXR-selective agonists) in
the absence of RAR ligands, since, under this condition, the
dissociation of corepressors from the heterodimer does not occur
[30]. However, the rexinoid receptor is not transcriptionally silent
since RAR activation produces larger biological effects in the
presence of a RXR ligand than in its absence, as originally
demonstrated by Lotan et al. for the inhibition of cancer cell
proliferation [31] and, more recently, by Idres et al. for the
induction of CYP26A1 [32]. The prevalent involvement of a RAR
in ATRA effects was also conﬁrmed by data obtained with RAR or
RXR antagonists (Fig. 1B and C).
Second, Rarb is induced before the stimulation of Slc1a1
expression, a ﬁnding consistent with its role as a transcription
factor needed for the synthesis of the transporter. Indeed,
cycloheximide suppresses Slc1a1 mRNA induction, indicating that
the effect requires a protein intermediate, which may work either at
transcriptional or at post-transcriptional level. However, ATRA
treatment does not change the half-life of Slc1a1 mRNA compared
with that of the housekeeping, ATRA-independent Gapdh (Fig. 3A).
On the contrary, under the same conditions, the post-transcriptional
effect of ATRA on another target gene, such as Plp [8], is readily
observed as an increase in the messenger half-life (Fig. 3C). Similar
effects have been detected in C6 cells for other ATRA target genes,
such as β1-adrenergic receptor [33] and connexin 43 [34]. It is,
therefore, likely that the protein intermediate required for Slc1a1
induction is a factor acting at the transcriptional level. A possible
candidate is RFX1, since the expression of human RFX1 was found to
stimulate Slc1a1 expression in C6 cells [5]. However, endogenous
Rfx1 is not induced in C6 cells during ATRA treatment at both mRNA
and protein level, thus rendering unlikely its involvement in ATRA-
dependent Slc1a1 regulation. On the contrary, Rarb is a typical,
direct ATRA target gene [9] and its induction is readily detected at
early times of ATRA treatment of C6 cells. Moreover, also RARβ
proteins are greatly induced at early ATRA treatment times so that
high levels of these receptors are present when Slc1a1 expression is
stimulated.
Third, and more importantly, Rarb silencing markedly inhibits the
induction of the transporter. The silencing approach adopted here is
quite effective, producing a marked fall in Rarb mRNA levels both in
ATRA-treated and in control cells. In particular, Rarb induction is
suppressed by almost 70%. The inhibitory effect on Slc1a1 is
comparable, indicating a strong relationship between RARβ expres-sion and Slc1a1 induction. The speciﬁcity of the inhibition is
demonstrated by the smaller effect of the same protocol on the
induction of Plp mRNA (not shown).
These results point to Slc1a1 as a RARβ-dependent ATRA target
gene, although they do not allow to identify the precise mechanism
underlying the effect. Indeed, it is possible that RARβ acts at genomic
level, as a classical transcription factor, but the data presented would
be also compatible with a non genomic effect of RARβ, as most
recently demonstrated for ATRA stimulation of iodide transport in
breast cancer cells [11]. Interestingly, two non repeating RARβ binding
sites are present at −191 bp and at −2696 bp of the rat Slc1a1 gene
(as identiﬁed through TESS: Transcription Element Search Software
on the WWW, URL: http://www.cbil.upenn.edu/tess). Similar
sequences are present also in the mouse Slc1a1 gene but not in the
human counterpart. Further experiments are needed to characterize
the role of these sequences, as well as to identify the RARβ isoform
involved in Slc1a1 induction.
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